https://www.massachusettsweekly.com/article/908356600-respiratory-care-professor-medtech-co-founder-presents-novel-neonate-breathing-technology-at-pas-meeting-in-boston Massachusetts Weekly en PressRelease 2026-04-27T11:38:39+00:00 Respiratory Care Professor, MedTech Co-Founder Presents Novel Neonate Breathing Technology at PAS Meeting in Boston https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24201100-brian-walsh-phd-chairman-of-t-1023x1160.jpeg https://www.massachusettsweekly.com/article/908368739-choosing-a-global-high-purity-fluorinated-building-blocks-vendor-for-modern-labs-aifchem Massachusetts Weekly en PressRelease 2026-04-27T05:08:32+00:00 Choosing a Global High-Purity Fluorinated Building Blocks Vendor for Modern Labs: AiFChem https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24841275-high-purity-fluorinated-buildin-1116x746.png https://www.massachusettsweekly.com/article/908368419-strategic-advantages-of-partnering-with-a-global-high-purity-heterocyclic-building-blocks-supplier-aifchem Massachusetts Weekly en PressRelease 2026-04-27T05:08:09+00:00 Strategic Advantages of Partnering with a Global High-Purity Heterocyclic Building Blocks Supplier: AiFChem https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24841273-global-high-purity-heterocyclic-757x600.png https://www.massachusettsweekly.com/article/908452226-addgene-reinforces-its-expanding-role-in-research-with-new-brand Massachusetts Weekly en PressRelease 2026-04-27T13:30:00+00:00 Addgene Reinforces Its Expanding Role in Research with New Brand https://ml.globenewswire.com/media/e4b4a6b0-9eac-49c5-852f-53fce9ecf258/small/addgene-logo-blue-png.png https://www.massachusettsweekly.com/article/908452232-signnow-launches-docgen-api-to-automate-business-document-creation-and-close-the-gap-between-data-and-signature Massachusetts Weekly en PressRelease 2026-04-27T13:30:00+00:00 SignNow Launches Docgen API to Automate Business Document Creation and Close the Gap Between Data and Signature https://ml.globenewswire.com/media/aab78b76-7606-4e1a-ac9e-3519885f79d4/medium/docgen-api-by-signnow.png https://www.massachusettsweekly.com/article/908452251-harvard-apparatus-regenerative-technology-announces-first-patient-treated-with-cellspan-esophageal-implant-at-mayo-clinic Massachusetts Weekly en PressRelease 2026-04-27T13:30:00+00:00 Harvard Apparatus Regenerative Technology Announces First Patient Treated with Cellspan Esophageal Implant at Mayo Clinic https://ml.globenewswire.com/media/686ae558-8768-4fc3-bdce-87ae3b318dd6/small/hrgn-logo-jpg.jpg https://www.massachusettsweekly.com/article/908447950-alpha-tau-announces-presentation-of-pancreatic-cancer-data-at-upcoming-asco-annual-meeting-showcasing-combined-results-from-three-alpha-dart Massachusetts Weekly en PressRelease 2026-04-27T13:01:00+00:00 Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies https://ml.globenewswire.com/media/a9de6f03-a487-4934-98e9-d25cdb4c8bed/small/atm-logo-jpg.jpg https://www.massachusettsweekly.com/article/908443320-akari-therapeutics-secures-australian-patent-approval-further-expanding-global-protection-of-its-proprietary-ph1-rna-splicing-modulator-adc-payload Massachusetts Weekly en PressRelease 2026-04-27T12:35:00+00:00 Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload https://ml.globenewswire.com/media/8d978f50-07a9-40a3-be69-45f51ccd94d9/small/akari-logo-1-jpg.jpg https://www.massachusettsweekly.com/article/908438912-cerence-to-announce-fiscal-second-quarter-results-on-may-7-2026 Massachusetts Weekly en PressRelease 2026-04-27T12:00:00+00:00 Cerence to Announce Fiscal Second Quarter Results on May 7, 2026 https://ml.globenewswire.com/media/873690ee-866c-4dea-9808-10aecc02890f/small/cerence-ai-logo-full-color-h-1-png.png https://www.massachusettsweekly.com/article/908439016-avalyn-strengthens-leadership-team-to-support-long-term-growth-with-appointments-of-industry-leaders-adam-golden-and-frank-salisbury Massachusetts Weekly en PressRelease 2026-04-27T12:00:00+00:00 Avalyn Strengthens Leadership Team to Support Long-Term Growth with Appointments of Industry Leaders Adam Golden and Frank Salisbury https://ml.globenewswire.com/media/84d7bff4-ce17-433b-8c71-aa20c30f9f43/small/avalyn-logo-final-png.png https://www.massachusettsweekly.com/article/908439020-replimune-to-present-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting Massachusetts Weekly en PressRelease 2026-04-27T12:00:00+00:00 Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting https://ml.globenewswire.com/media/NzU1N2M2NzEtNmRkNS00ODQ0LTg0YmQtZTVjMDZhZTRlNjQ1LTExMjIxMDEtMjAyNi0wNC0yNy1lbg==/tiny/Replimune-Inc-.png https://www.massachusettsweekly.com/article/908434376-tovecimig-demonstrates-statistically-significant-benefit-in-companion-002-randomized-phase-2-3-study-in-patients-with-biliary-tract-cancer Massachusetts Weekly en PressRelease 2026-04-27T11:30:00+00:00 Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer https://ml.globenewswire.com/media/b8470129-5d30-4368-8074-d77404b65be8/small/compass-logo-rgb-outlines-png.png https://www.massachusettsweekly.com/article/908434378-nima-s-next-gen-portable-gluten-sensor-wins-gold-stevie-award-for-achievement-in-product-innovation Massachusetts Weekly en PressRelease 2026-04-27T11:30:00+00:00 NIMA’s Next-Gen Portable Gluten Sensor Wins Gold Stevie® Award for Achievement in Product Innovation https://ml.globenewswire.com/media/a025c49c-a270-4041-92e3-76d50d9bc27f/medium/nima-is-the-2026-gold-stevie-award-winner.png https://www.massachusettsweekly.com/article/908429883-fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results-for-first-quarter-2026 Massachusetts Weekly en PressRelease 2026-04-27T11:00:00+00:00 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026 https://ml.globenewswire.com/media/3434fc83-4bcf-4d3c-ae26-23e5b1fd4252/small/fulcrum-logo-primary-full-color-rgb-large-png.png https://www.massachusettsweekly.com/article/908429920-sionna-therapeutics-completes-enrollment-in-precision-cf-phase-2a-trial-evaluating-nbd1-stabilizer-sion-719-added-to-standard-of-care-in Massachusetts Weekly en PressRelease 2026-04-27T11:00:00+00:00 Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis https://ml.globenewswire.com/media/0cda8c25-e758-4f0d-86f2-875df8411a9a/small/sionna-png.png https://www.massachusettsweekly.com/article/908430156-intellia-therapeutics-reports-positive-phase-3-results-in-hereditary-angioedema-marking-a-global-first-for-in-vivo-gene-editing Massachusetts Weekly en PressRelease 2026-04-27T11:00:00+00:00 Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing https://ml.globenewswire.com/media/9b6b17bb-c8a4-4009-b5f8-8cadb4d2296a/small/intellia-jpg.jpg https://www.massachusettsweekly.com/article/908430163-intellia-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-lonvoguran-ziclumeran-lonvo-z-as-a-one-time-treatment Massachusetts Weekly en PressRelease 2026-04-27T11:00:00+00:00 Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema https://ml.globenewswire.com/media/9b6b17bb-c8a4-4009-b5f8-8cadb4d2296a/small/intellia-jpg.jpg https://www.massachusettsweekly.com/article/908430198-ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences Massachusetts Weekly en PressRelease 2026-04-27T11:00:00+00:00 Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences https://ml.globenewswire.com/media/20ee0f50-7288-4f81-8546-f2ad2050ddbf/small/ocul-logo-jpg.jpg https://www.massachusettsweekly.com/article/908425638-fulcrum-therapeutics-appoints-josh-lehrer-to-its-board-of-directors Massachusetts Weekly en PressRelease 2026-04-27T10:55:00+00:00 Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors https://ml.globenewswire.com/media/3434fc83-4bcf-4d3c-ae26-23e5b1fd4252/small/fulcrum-logo-primary-full-color-rgb-large-png.png https://www.massachusettsweekly.com/article/908418144-relay-therapeutics-announces-clinical-data-for-zovegalisib-plus-atirmociclib-triplet-combination-supportive-of-further-development-in-frontline Massachusetts Weekly en PressRelease 2026-04-27T10:00:00+00:00 Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer https://ml.globenewswire.com/media/079b6db5-ce81-4a81-9cde-d97f86c569ae/small/logo-banner-small-png.png https://www.massachusettsweekly.com/article/907620144-learn-to-spot-scams-launches-comprehensive-digital-security-platform-to-combat-rising-online-fraud-and-identity-theft Massachusetts Weekly en PressRelease 2026-04-25T18:38:50+00:00 Learn to Spot Scams Launches Comprehensive Digital Security Platform to Combat Rising Online Fraud and Identity Theft https://www.massachusettsweekly.com/article/908097107-study-shows-implicity-s-new-agnostic-cloud-based-ai-algorithm-further-reduces-false-alerts-even-after-manufacturer-ai-filtering-in-modern-devices Massachusetts Weekly en PressRelease 2026-04-25T15:00:00+00:00 Study Shows Implicity’s New Agnostic Cloud-Based AI Algorithm Further Reduces False Alerts Even After Manufacturer AI Filtering in Modern Devices https://ml.globenewswire.com/media/d7822800-7d4d-420d-aa7f-89a50a370756/small/implicity-logo-jpg.jpg